Google
HRMY 株価分析 — Harmony Biosciences Holdings (Healthcare >> Biotechnology)
HRMY に関するよくある質問
HRMYのPER（株価収益率）は？
Harmony Biosciences Holdings（HRMY）は現在PER 14.15倍で取引されています。
HRMYのROE（自己資本利益率）は？
Harmony Biosciences HoldingsのROEは16.00%です。
HRMYの配当利回りは？
Harmony Biosciences Holdingsの配当利回りは0.00%です。
HRMYの品質スコア（Quality Score）は？
当社のAIはHRMYの総合財務品質を100点中62点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
HRMYは今が買い時ですか？
当社AIのタイミングスコアは100点中91点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
HRMYはどのセクターに属しますか？
Harmony Biosciences HoldingsはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
HRMY AI Analysis Summary
Our AI summary for HRMY: Harmony Biosciences Holdings (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 14.15, ROE of 16.00%, a dividend yield of 0.00%. Its financial Quality Score stands at 62/100 — mid-range fundamentals relative to the market. The AI Timing Score is 91/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 38.78
Price
3.18
(8.93%)
Day Change
|
|
|---|
HRMY, ファンダメンタルスコアはok ( ファンダメンタル = 62) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- NEUTRAL
- Signal Description
- Company financial health is OK
- Reason
-
ROEの伸びが低い
昨年度のROEが一昨年比で低い
ROAの伸びが低い
Last-year ROA is lower than last-2-years ROA.
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not quite good , financial health is not quite good , and ability to make profit is ok , ...
| Deepscope 分析 |
|
51% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 95 |
| Magic Formula Rank by ROA |
467
|
| Magic Formula Rank by ROE |
467
|
| Magic Formula Rank by ROIC |
350
|
| Price | 38.78 |
| PBV / Sector |
2.26 / 44,022.72
|
| Earning Per Share | 2.74 |
| PE / Sector |
14.15 / 19.17
|
| PEG or PE/Growth / Sector |
-16.85 / 1.24
|
| Average 1M Daily Value |
31.69 M
GREAT
|
| Average 1W Daily Value |
32.51 M
GREAT
|
| Timing Factors |
|
71% |
| Financial Health |
|
56% |
| ポイントになる統計 |
|
64% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-05 08:00:20 |
| Symbol | HRMY |
| Name | HARMONY BIOSCIENCES HOLDINGS |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 57.89 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 2,060.98 / 9,586.08 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 630 West Germantown Pike, Plymouth Meeting, PA, United States, 19462
Phone: 484 539 9800
Website: https://www.harmonybiosciences.com
Employees: 293
Sector: Healthcare >> Biotechnology
Description: Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 2 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and Pitolisant High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies; CBS105 for the treatment-resistant narcolepsy; and CBS104 for refractory epilepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
